Cited by 34Reproductive Health and ContraceptionMenopause: Health Impacts and TreatmentsInternational Human Rights and Reproductive Law

Triphasic oral contraceptives: review and comparison of various regimens

Open access
Cedars, Marcelle I·2002·Fertility and Sterility

Abstract

Objective To review and compare the risk-benefit profile of triphasic oral contraceptives with that of low-dose monophasic oral contraceptives.Design Literature on currently marketed triphasics and monophasics.Patient(s) Healthy women of reproductive age.Main outcome measure(s) Comparison of the rationale for development, composition, mechanism, efficacy, menstrual cycle control, side effects, health benefits, and risk-benefit profile.Result(s) All triphasics contain ethinyl estradiol (0.025-0.040 mg/d) and one of several progestins in doses (0.05-1.0 mg/d) related to their relative potencies, which are substantially lower overall (total dose) than those in monophasics. The triphasics are highly efficacious. In general, menstrual cycle control and side effects are similar in both types, but triphasics containing the newer progestins (desogestrel, gestodene, and norgestimate) have better cycle control and a reduced incidence of androgenic side effects compared with those with norethindrone or levonorgestrel. Both triphasics and monophasics have minimal effects on carbohydrate and lipid metabolism and hemostasis parameters, and therefore comparable low risks of coronary heart disease. The health benefits of triphasics and monophasics are similar and include decreased incidence of unwanted and ectopic pregnancies, ovarian cysts, endometrial and ovarian cancers, benign breast disease, and acute pelvic inflammatory disease; less menstrual blood loss and iron deficiency anemia; and lower frequency of irregular bleeding and menorrhagia.Conclusion(s) The risk-benefit profiles of both triphasics and monophasics are favorable and similar.

Integrity signals

Registry

Crossref · 10.1016/s0015-0282(01)02927-2

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Newer progestins have selectivity ratios for the progesterone receptor seven to eight times higher than those of older progestins.

    “Progestins also differ in their selectivity for the progesterone receptor, with newer progestins having selectivity ratios seven to eight times higher than those of older progestins [54].”
  • New oral contraceptive formulations contain less than 20% of the earliest preparations.

    “New oral contraceptive formulations have been developed to contain the minimum steroid doses necessary to inhibit ovulation, and current formulations contain less than 20% of the earliest preparations [54].”

Cites

Flagged first, then by citations

2 of the 71 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Cedars, M. I.
Affiliations
University of California, San Francisco (US)
Corresponding author
Cedars, Marcelle I
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2002-01
Volume
77
Issue
1
Pages
1-14
ISSN
0015-0282 (ISSN-L)
OpenAlex
W2071155073
Cited by
34
References
71
Citations by year
2025: 2 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 1 · 2018: 3 · 2016: 1 · 2014: 1
FWCI
3.49
Type
journal article
Language
en
Open access
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Social Sciences › Political Science and International Relations › International Human Rights and Reproductive Law
Keywords
triphasic oral contraceptives, monophasic oral contraceptives, ethinyl estradiol, progestins, desogestrel, gestodene, norgestimate, norethisterone, levonorgestrel, menstrual cycle regulation, androgenic side effects, coronary heart disease risk, contraceptive efficacy, ovarian cancer prevention, endometrial cancer prevention, benign breast disease, pelvic inflammatory disease, iron deficiency anemia, risk-benefit profile
MeSH terms
Contraceptives, Oral, Combined, Drug Administration Schedule, Female, Humans, Menstrual Cycle, Reproduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review